ArticleACS omega2025
Chitosan Hydrogels Enriched with Biocompounds Extracted from Marine Sponges: Potential to Modulate the Inflammatory Process in an
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Croaker Fish Bone-Derived Hydroxyapatite as a Sustainable Source for 3D-Printed Scaffolds for Bone Regeneration.Marine drugs · 2026Article
- Analysis of the Anti-inflammatory Effects of a Delivery System Based on Alginate Hydrogels Enriched with Bioactive Compounds from Marine Sponge Dysidea robusta.Applied biochemistry and biotechnology · 2026Article
- Green Marine Collagen-Chitosan Composites with Biocompatible, Hemostatic, and Pro-Healing Performance.ACS applied bio materials · 2026Article
- Bioglass-Reinforced Spongin-Like Collagen Scaffolds for Osteoporotic Bone Tissue Engineering.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogels are recognized as effective drug delivery systems in medical and pharmaceutical applications. Among them, chitosan (CH) hydrogels stand out for their biocompatibility, biodegradability, and ability to release bioactive substances. This is especially promising for anti-inflammatory compounds since inflammation is associated with various diseases. Although effective, conventional anti-inflammatory drugs, when administered orally and over the long term, can cause side effects, stimulating the search for natural alternatives and safer release systems. Furthermore, in the search for natural bioactives, it is known that a source of biocompounds that is still little explored, despite its potential, is the marine sponge Dysidea robusta. The aim of this study was to develop and characterize chitosan-based hydrogels enriched with biocompounds derived from the marine sponge Dysidea robusta. Four chitosan hydrogel formulations were synthesized using varying concentrations of urease and urea, and their physical and morphological properties were evaluated using the mass loss test and techniques such as Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and rheology. Seven biocompounds from the marine sponge Dysidea robusta (DR1 to DR7) were obtained and incorporated into a hydrogel formulation with optimal gelation time, stability, and presence of pores (H3). Drug release capacity was analyzed, as well as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.